3-{1-[2-(4-chlorophenoxy)acetyl]piperidin-4-yl}-4-[(4-fluorophenyl)methyl]-4,5-dihydro-1H-1,2,4-triazol-5-one

Catalog No. :
ACRGGX905
CAS No. :
1775524-46-3
Molecular Formula :
C22H22ClFN4O3
Molecular Weight :
444.89

IUPAC Name:5-(1-(2-(4-chlorophenoxy)acetyl)piperidin-4-yl)-4-(4-fluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one

3-{1-[2-(4-chlorophenoxy)acetyl]piperidin-4-yl}-4-[(4-fluorophenyl)methyl]-4,5-dihydro-1H-1,2,4-triazol-5-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-{1-[2-(4-chlorophenoxy)acetyl]piperidin-4-yl}-4-[(4-fluorophenyl)methyl]-4,5-dihydro-1H-1,2,4-triazol-5-one
IUPAC Name5-(1-(2-(4-chlorophenoxy)acetyl)piperidin-4-yl)-4-(4-fluorobenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
MDL No.MFCD28805984
Molecular FormulaC22H22ClFN4O3
Molecular Weight444.89
SMILESO=C1N(CC2=CC=C(F)C=C2)C(C3CCN(C(COC4=CC=C(Cl)C=C4)=O)CC3)=NN1
InChI KeyJCQFVTLEOAOGRK-UHFFFAOYSA-N
Synonym3-{1-[2-(4-chlorophenoxy)acetyl]piperidin-4-yl}-4-[(4-fluorophenyl)methyl]-4,5-dihydro-1H-1,2,4-triazol-5-one;3H-1,2,4-Triazol-3-one, 5-[1-[2-(4-chlorophenoxy)acetyl]-4-piperidinyl]-4-[(4-fluorophenyl)methyl]-2,4-dihydro-
CAS No.1775524-46-3

Synthetic Route by SureRoute

1. ACRGGX905 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACIREQ137 route compound structure diagram
    ACIREQ13713730-98-8 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRGGX905 route product structure diagram
    ACRGGX9051775524-46-3
Inquiry

2. ACRGGX905 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRGGX905 route product structure diagram
    ACRGGX9051775524-46-3
Inquiry

Comments (0)